Latest news with #Insulatard
Time of India
22-04-2025
- Business
- Time of India
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Pharmaceutical giant Novo Nordisk is discontinuing the country's largest selling insulin, Human Mixtard , along with other insulins. The move could shake up the diabetes market, TOI it being under price control, Human Mixtard alone is a Rs 800 crore brand for the company in India. The phase out could further impact the pharmaceutical's top brands in the Rs 5,000 crore insulin market including Actrapid, Insulatard , Insulin Detemir and Levemir and Xultophy, which are marketed primarily in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen).TOI accessed documents that said the company recently informed marketing partner, Abbott India that the products would be discontinued once the current stocks are exhausted. This could take about six decision comes as the Danish company's global strategy to prioritise newer, patented diabetes and weight loss therapies including Ozempic and Wegovy, due to their higher profitability, sources told TOI. It also is in line with its plans to introduce these therapies in the Indian market this Nordisk, as a part of its global strategy is discontinuing earlier generation insulin products the company plans to continue selling Human Mixtard, Actrapid and Insulatard, in vials, which can be delivered to patients through might lead to limited access as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing, and reduced stigma.(With TOI inputs)
Time of India
22-04-2025
- Health
- Time of India
Novo Nordisk to phase out its largest insulin brand in India
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country's largest selling insulin, Human Mixtard, among other older insulin brands in India. Tired of too many ads? go ad free now Human Mixtard alone is a Rs 800 crore brand for Novo Nordisk in India, despite it being under price control. Besides Human Mixtard, the phase-out could impact its top brands in the Rs 5,000 crore insulin market including Actrapid, Insulatard, Insulin Detemir and Levemir and Xultophy — marketed mostly in the format of pre-filled disposable pen and cartridges (Penfill and FlexPen). The company recently informed its marketing partner, Abbott India that the products would be discontinued once the current stocks are exhausted, documents accessed by TOI said. This could take about six months. The decision is in line with the global strategy of the Danish company to prioritise newer, patented blockbuster diabetes and weight loss therapies including Ozempic and Wegovy , due to their higher profitability, sources said. Also, it seems to be potentially in line with its plans to introduce these therapies in the Indian market this year. As part of its global strategy, earlier generation insulin products will be discontinued globally in a gradual manner. An email sent on April 17 to the company went unanswered. However, the company plans to continue selling Human Mixtard, Actrapid and Insulatard, in vials — which can be delivered to patients through injections. This may limit the access further as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected with syringes, due to its accuracy, ease of dosing, and reduced stigma, a survey said earlier.
